首页 > 最新文献

Anticancer research最新文献

英文 中文
Clinical Significance of Granzyme B Gene Expression in Pathological Stage II/III Gastric Cancer After Curative Gastrectomy. 治愈性胃切除术后病理 II/III 期胃癌中 Granzyme B 基因表达的临床意义
IF 1.6 4区 医学 Q4 ONCOLOGY Pub Date : 2024-10-01 DOI: 10.21873/anticanres.17282
Takashi Oshima, Itaru Hashimoto, Yukihiko Hiroshima, Yayoi Kimura, Mie Tanabe, Yuta Nakayama, Shinsuke Nagasawa, Kyohei Kanematsu, Toru Aoyama, Takanobu Yamada, Takashi Ogata, Yohei Miyagi

Background/aim: Granzyme B (GZMB) is mainly produced by natural killer (NK) cells and activated CD8-positive T cells to induce tumor cell apoptosis. We analyzed the significance of GZMB expression in gastric cancer (GC) tissues from patients with pathological (p)Stage II/III GC after curative resection.

Patients and methods: Patients with pStage II/III GC who received curative resection (n=253) were included and the expression levels of GZMB in GC tissues and in the adjacent normal mucosa were measured using quantitative real-time polymerase chain reaction. The expression levels in GC tissues and clinicopathological features and overall survival (OS) were compared in these patients.

Results: GZMB expression levels were significantly higher in GC tissues than in the adjacent normal mucosa. GZMB expression levels in GC tissues were not associated with any clinicopathological features. The 5-year OS rate in the high-GZMB expression group was significantly better than that in the low-expression group (5-year survival rate 72.0% vs. 55.7%; p=0.009). Furthermore, on multivariate analysis, high-GZMB expression was an independent factor for better OS (hazard ratio=0.652; 95% confidence interval=0.432-0.987; p=0.043).

Conclusion: In patients with locally advanced GC after curative resection, GZMB expression in GC tissue may be a useful prognostic marker.

背景/目的:颗粒酶B(GZMB)主要由自然杀伤细胞(NK)和活化的CD8阳性T细胞产生,诱导肿瘤细胞凋亡。我们分析了治愈性切除术后病理(p)II/III期胃癌(GC)患者组织中GZMB表达的意义:纳入接受根治性切除术的p期II/III GC患者(n=253),采用定量实时聚合酶链反应法测定GZMB在GC组织和邻近正常黏膜中的表达水平。结果发现,GZMB在GC组织中的表达水平明显高于在邻近正常粘膜中的表达水平:结果:GC组织中GZMB的表达水平明显高于邻近的正常黏膜。GC组织中GZMB的表达水平与任何临床病理特征无关。GZMB高表达组的5年生存率明显优于低表达组(5年生存率为72.0% vs. 55.7%; p=0.009)。此外,在多变量分析中,GZMB高表达是改善OS的独立因素(危险比=0.652;95%置信区间=0.432-0.987;P=0.043):结论:对于根治性切除术后的局部晚期GC患者,GC组织中GZMB的表达可能是一个有用的预后标志物。
{"title":"Clinical Significance of Granzyme B Gene Expression in Pathological Stage II/III Gastric Cancer After Curative Gastrectomy.","authors":"Takashi Oshima, Itaru Hashimoto, Yukihiko Hiroshima, Yayoi Kimura, Mie Tanabe, Yuta Nakayama, Shinsuke Nagasawa, Kyohei Kanematsu, Toru Aoyama, Takanobu Yamada, Takashi Ogata, Yohei Miyagi","doi":"10.21873/anticanres.17282","DOIUrl":"https://doi.org/10.21873/anticanres.17282","url":null,"abstract":"<p><strong>Background/aim: </strong>Granzyme B (GZMB) is mainly produced by natural killer (NK) cells and activated CD8-positive T cells to induce tumor cell apoptosis. We analyzed the significance of GZMB expression in gastric cancer (GC) tissues from patients with pathological (p)Stage II/III GC after curative resection.</p><p><strong>Patients and methods: </strong>Patients with pStage II/III GC who received curative resection (n=253) were included and the expression levels of GZMB in GC tissues and in the adjacent normal mucosa were measured using quantitative real-time polymerase chain reaction. The expression levels in GC tissues and clinicopathological features and overall survival (OS) were compared in these patients.</p><p><strong>Results: </strong>GZMB expression levels were significantly higher in GC tissues than in the adjacent normal mucosa. GZMB expression levels in GC tissues were not associated with any clinicopathological features. The 5-year OS rate in the high-GZMB expression group was significantly better than that in the low-expression group (5-year survival rate 72.0% vs. 55.7%; p=0.009). Furthermore, on multivariate analysis, high-GZMB expression was an independent factor for better OS (hazard ratio=0.652; 95% confidence interval=0.432-0.987; p=0.043).</p><p><strong>Conclusion: </strong>In patients with locally advanced GC after curative resection, GZMB expression in GC tissue may be a useful prognostic marker.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"44 10","pages":"4537-4542"},"PeriodicalIF":1.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142339873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Factors Limiting Ostomy Reversal After Cytoreductive Surgery for Ovarian Cancer: A Retrospective Study. 卵巢癌清创手术后限制造口术逆转的因素:一项回顾性研究
IF 1.6 4区 医学 Q4 ONCOLOGY Pub Date : 2024-10-01 DOI: 10.21873/anticanres.17270
Beatriz Navarro Santana, Frederic Guyon, Octavio Arencibia, Guillaume Babin, Eudaldo Tommasetti, Daniel González, Sabrina Piedimonte, Alicia Martín Martínez

Background/aim: To investigate the factors related to non-reversal of ostomy after cytoreductive surgery in ovarian cancer. In many women with ovarian cancer, transitory ostomies are performed to limit the consequences of anastomotic leak. Although intended to be temporary, a proportion of these ostomies might never be reversed.

Patients and methods: This was a retrospective study of patients with 2014 International Federation of Obstetrics and Gynecology stage IIB-IVB ovarian cancer requiring a transitory ostomy during primary or secondary cytoreductive surgery at the Bergonie Institute, France, and the University Hospital of Las Palmas, Spain, between January 2012 and December 2022. Rate of ostomy reversal, its timing (weeks) and postoperative complications were assessed. Multivariate logistic regression analysis was performed to identify limiting factors for ostomy reversal.

Results: During the study period, we reviewed data on 181 consecutive patients with ovarian cancer with transitory ostomy creation; 89 (49.2%) patients were not candidates for an ostomy reversal surgery because of disease progression (n=65), death (n=16), and patient's refusal of surgery (n=8). A total of 92 patients were candidates for reversal surgery and were therefore included in the final analysis. In total, 57 (62%) patients had their ostomy reversed. The mean time from ostomy creation to ostomy closure was 47.7 (standard deviation=33.1) weeks. Hartmann's procedure (leaving a rectal stump of 5-6 cm) was identified as an independent predictive factor for non-reversal of ostomy (odds ratio=6.42, 95% confidence interval=1.61-25.53; p=0.008). Complications after ostomy reversal occurred in 32 patients (34.8%).

Conclusion: Hartmann's procedure is a limiting factor for ostomy reversal in patients with ovarian cancer. We recommend avoiding Hartmann's procedure during cytoreductive surgery, even after colorectal anastomotic leak.

背景/目的:研究卵巢癌细胞切除手术后不逆行造口术的相关因素。在许多卵巢癌女性患者中,为了限制吻合口漏造成的后果,需要实施过渡性造口术。虽然这些造口是临时性的,但其中一部分可能永远无法逆转:这是一项回顾性研究,研究对象是2012年1月至2022年12月期间在法国贝戈尼研究所(Bergonie Institute)和西班牙拉斯帕尔马斯大学医院(University Hospital of Las Palmas)接受初级或二级细胞减灭术、需要临时造口的2014年国际妇产科联盟IIB-IVB期卵巢癌患者。对造口翻转率、时间(周)和术后并发症进行了评估。我们进行了多变量逻辑回归分析,以确定造口翻转的限制因素:在研究期间,我们回顾了连续 181 例卵巢癌患者的数据,其中有 89 例(49.2%)患者因疾病进展(65 例)、死亡(16 例)和患者拒绝手术(8 例)而不适合接受造口翻转手术。共有 92 名患者符合逆转手术的条件,因此被纳入最终分析。共有 57 名患者(62%)接受了造口翻转手术。从造口建立到造口关闭的平均时间为 47.7 周(标准差=33.1 周)。哈特曼手术(留下 5-6 厘米的直肠残端)被认为是不逆转造口的独立预测因素(几率比=6.42,95% 置信区间=1.61-25.53;P=0.008)。32名患者(34.8%)在逆转造口术后出现并发症:结论:哈特曼手术是卵巢癌患者逆转造口术的限制因素。结论:哈特曼手术是卵巢癌患者进行造口翻转术的限制因素,我们建议在进行细胞切除手术时避免哈特曼手术,即使是在结直肠吻合口漏之后。
{"title":"Factors Limiting Ostomy Reversal After Cytoreductive Surgery for Ovarian Cancer: A Retrospective Study.","authors":"Beatriz Navarro Santana, Frederic Guyon, Octavio Arencibia, Guillaume Babin, Eudaldo Tommasetti, Daniel González, Sabrina Piedimonte, Alicia Martín Martínez","doi":"10.21873/anticanres.17270","DOIUrl":"https://doi.org/10.21873/anticanres.17270","url":null,"abstract":"<p><strong>Background/aim: </strong>To investigate the factors related to non-reversal of ostomy after cytoreductive surgery in ovarian cancer. In many women with ovarian cancer, transitory ostomies are performed to limit the consequences of anastomotic leak. Although intended to be temporary, a proportion of these ostomies might never be reversed.</p><p><strong>Patients and methods: </strong>This was a retrospective study of patients with 2014 International Federation of Obstetrics and Gynecology stage IIB-IVB ovarian cancer requiring a transitory ostomy during primary or secondary cytoreductive surgery at the Bergonie Institute, France, and the University Hospital of Las Palmas, Spain, between January 2012 and December 2022. Rate of ostomy reversal, its timing (weeks) and postoperative complications were assessed. Multivariate logistic regression analysis was performed to identify limiting factors for ostomy reversal.</p><p><strong>Results: </strong>During the study period, we reviewed data on 181 consecutive patients with ovarian cancer with transitory ostomy creation; 89 (49.2%) patients were not candidates for an ostomy reversal surgery because of disease progression (n=65), death (n=16), and patient's refusal of surgery (n=8). A total of 92 patients were candidates for reversal surgery and were therefore included in the final analysis. In total, 57 (62%) patients had their ostomy reversed. The mean time from ostomy creation to ostomy closure was 47.7 (standard deviation=33.1) weeks. Hartmann's procedure (leaving a rectal stump of 5-6 cm) was identified as an independent predictive factor for non-reversal of ostomy (odds ratio=6.42, 95% confidence interval=1.61-25.53; p=0.008). Complications after ostomy reversal occurred in 32 patients (34.8%).</p><p><strong>Conclusion: </strong>Hartmann's procedure is a limiting factor for ostomy reversal in patients with ovarian cancer. We recommend avoiding Hartmann's procedure during cytoreductive surgery, even after colorectal anastomotic leak.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"44 10","pages":"4413-4418"},"PeriodicalIF":1.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142339879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inhibition of Epithelial-Mesenchymal Transition and Migration in Cisplatin-resistant Cancer Through Combined Treatment With Cisplatin and SH003. 通过顺铂和 SH003 联合治疗抑制顺铂耐药癌症的上皮-间质转化和迁移
IF 1.6 4区 医学 Q4 ONCOLOGY Pub Date : 2024-10-01 DOI: 10.21873/anticanres.17265
Hyeong Sim Choi, Jeong-Kui Ku, Seong-Gyu Ko, Pil-Young Yun

Background/aim: This study investigated the synergistic effects of combining cisplatin and SH003 treatment on the viability, apoptosis, cytotoxicity, migration and epithelial-mesenchymal transition (EMT) in cisplatin-resistant cancer cell lines YD-8/CIS, YD-9/CIS and YD-38/CIS.

Materials and methods: The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used to assess cell viability, while trypan blue exclusion assay was used to evaluate cytotoxicity. Flow cytometry and western blot analysis measured apoptotic cell death. Wound-healing assays evaluated cell migration and EMT markers. Combination index (CI) plots were used to evaluate the combinatory effects of the treatment.

Results: Combination therapy significantly reduced cell viability more effectively than each agent alone, as demonstrated by the MTT assay, with CI plots confirming notable synergism. Trypan blue exclusion assays indicated increased cell death and cytotoxicity in combination treatment than in both monotherapies, although the increase was not significant. Flow cytometry and western blot analysis revealed no significant synergistic effect on apoptotic cell death. However, wound-healing assays revealed that the combination of cisplatin and SH003 significantly inhibited cell migration and regulated EMT markers, indicating the potential reversal of EMT.

Conclusion: Combining cisplatin and SH003 therapy may potentially be a more effective strategy for treating cisplatin-resistant cancer by increasing cytotoxicity and inhibiting metastasis. Further research is required to elucidate the underlying mechanisms and evaluate the in vivo efficacy of this combination therapy.

背景/目的:本研究探讨了顺铂和SH003联合治疗对顺铂耐药癌细胞株YD-8/CIS、YD-9/CIS和YD-38/CIS的活力、凋亡、细胞毒性、迁移和上皮-间质转化(EMT)的协同作用:3-(4,5-二甲基噻唑-2-基)-2,5-二苯基溴化四氮唑(MTT)检测法用于评估细胞活力,胰蓝排除法用于评估细胞毒性。流式细胞术和 Western 印迹分析测定了细胞凋亡情况。伤口愈合试验评估了细胞迁移和 EMT 标记。联合指数(CI)图用于评估治疗的联合效应:结果:如 MTT 试验所示,联合疗法比单独使用每种药物更有效地降低了细胞活力,CI 图证实了明显的协同作用。胰蓝排除试验表明,与两种单一疗法相比,联合疗法增加了细胞死亡和细胞毒性,但增幅并不明显。流式细胞术和 Western 印迹分析表明,联合疗法对细胞凋亡没有明显的协同作用。然而,伤口愈合试验显示,顺铂和SH003联合用药可明显抑制细胞迁移并调节EMT标记物,这表明联合用药有可能逆转EMT:结论:顺铂和SH003联合治疗可能是治疗顺铂耐药癌症的一种更有效的策略,它能增加细胞毒性并抑制转移。要阐明这种联合疗法的内在机制并评估其体内疗效,还需要进一步的研究。
{"title":"Inhibition of Epithelial-Mesenchymal Transition and Migration in Cisplatin-resistant Cancer Through Combined Treatment With Cisplatin and SH003.","authors":"Hyeong Sim Choi, Jeong-Kui Ku, Seong-Gyu Ko, Pil-Young Yun","doi":"10.21873/anticanres.17265","DOIUrl":"https://doi.org/10.21873/anticanres.17265","url":null,"abstract":"<p><strong>Background/aim: </strong>This study investigated the synergistic effects of combining cisplatin and SH003 treatment on the viability, apoptosis, cytotoxicity, migration and epithelial-mesenchymal transition (EMT) in cisplatin-resistant cancer cell lines YD-8/CIS, YD-9/CIS and YD-38/CIS.</p><p><strong>Materials and methods: </strong>The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used to assess cell viability, while trypan blue exclusion assay was used to evaluate cytotoxicity. Flow cytometry and western blot analysis measured apoptotic cell death. Wound-healing assays evaluated cell migration and EMT markers. Combination index (CI) plots were used to evaluate the combinatory effects of the treatment.</p><p><strong>Results: </strong>Combination therapy significantly reduced cell viability more effectively than each agent alone, as demonstrated by the MTT assay, with CI plots confirming notable synergism. Trypan blue exclusion assays indicated increased cell death and cytotoxicity in combination treatment than in both monotherapies, although the increase was not significant. Flow cytometry and western blot analysis revealed no significant synergistic effect on apoptotic cell death. However, wound-healing assays revealed that the combination of cisplatin and SH003 significantly inhibited cell migration and regulated EMT markers, indicating the potential reversal of EMT.</p><p><strong>Conclusion: </strong>Combining cisplatin and SH003 therapy may potentially be a more effective strategy for treating cisplatin-resistant cancer by increasing cytotoxicity and inhibiting metastasis. Further research is required to elucidate the underlying mechanisms and evaluate the in vivo efficacy of this combination therapy.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"44 10","pages":"4359-4369"},"PeriodicalIF":1.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142339884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Significance of HRNR Expression in Patients With Stage II/III Gastric Cancer After Curative Gastrectomy. 胃切除术后 II/III 期胃癌患者 HRNR 表达的临床意义
IF 1.6 4区 医学 Q4 ONCOLOGY Pub Date : 2024-10-01 DOI: 10.21873/anticanres.17287
Takashi Oshima, Itaru Hashimoto, Yukihiko Hiroshima, Yayoi Kimura, Mie Tanabe, Yuta Nakayama, Shinsuke Nagasawa, Kyohei Kanematsu, Toru Aoyama, Takanobu Yamada, Takashi Ogata, Yohei Miyagi

Background/aim: The function of the S-100 protein family member hornerin (HRNR) in gastric cancer (GC) tissues is largely unknown. We researched the clinical significance of HRNR expression in GC tissues of patients with pathological (p)Stage II/III GC after curative resection.

Patients and methods: We included patients with pStage II/III GC who underwent curative gastrectomy (n=253). Expression levels of HRNR in GC tissue and in the adjacent normal mucosa were determined using quantitative real-time polymerase chain reaction. Clinicopathological features and overall survival (OS) were compared in patients with different HRNR expression levels in GC tissue.

Results: HRNR expression levels were significantly higher in GC tissues than in the adjacent normal mucosa. HRNR expression level in GC tissue showed sex differences. The 5-year OS rate in the high-HRNR expression group was significantly worse than that in the low-expression group (5-year survival 53.6% vs. 74.9%; p=0.004). Furthermore, on multivariate analysis, high-HRNR expression was an independent predictor of poor OS (hazard ratio=1.534; 95% confidence interval=1.130-2.618; p=0.011).

Conclusion: In patients with pStage II/III GC after curative gastrectomy, HRNR expression in GC tissue may be a useful prognostic marker.

背景/目的:S-100蛋白家族成员角蛋白(HRNR)在胃癌(GC)组织中的功能尚不清楚。我们研究了HRNR在接受根治性切除术的病理(p)II/III期GC患者的GC组织中表达的临床意义:我们纳入了接受根治性胃切除术的p期II/III GC患者(n=253)。采用定量实时聚合酶链反应法测定GC组织和邻近正常黏膜中HRNR的表达水平。比较了GC组织中不同HRNR表达水平患者的临床病理特征和总生存率(OS):结果:HRNR在GC组织中的表达水平明显高于邻近的正常粘膜。GC组织中的HRNR表达水平存在性别差异。高HRNR表达组的5年OS率明显低于低表达组(5年生存率为53.6%对74.9%;P=0.004)。此外,在多变量分析中,高HRNR表达是不良OS的独立预测因子(危险比=1.534;95%置信区间=1.130-2.618;P=0.011):结论:对于接受胃切除术的P期II/III GC患者,GC组织中HRNR的表达可能是一个有用的预后标志物。
{"title":"Clinical Significance of <i>HRNR</i> Expression in Patients With Stage II/III Gastric Cancer After Curative Gastrectomy.","authors":"Takashi Oshima, Itaru Hashimoto, Yukihiko Hiroshima, Yayoi Kimura, Mie Tanabe, Yuta Nakayama, Shinsuke Nagasawa, Kyohei Kanematsu, Toru Aoyama, Takanobu Yamada, Takashi Ogata, Yohei Miyagi","doi":"10.21873/anticanres.17287","DOIUrl":"https://doi.org/10.21873/anticanres.17287","url":null,"abstract":"<p><strong>Background/aim: </strong>The function of the S-100 protein family member hornerin (HRNR) in gastric cancer (GC) tissues is largely unknown. We researched the clinical significance of HRNR expression in GC tissues of patients with pathological (p)Stage II/III GC after curative resection.</p><p><strong>Patients and methods: </strong>We included patients with pStage II/III GC who underwent curative gastrectomy (n=253). Expression levels of HRNR in GC tissue and in the adjacent normal mucosa were determined using quantitative real-time polymerase chain reaction. Clinicopathological features and overall survival (OS) were compared in patients with different HRNR expression levels in GC tissue.</p><p><strong>Results: </strong>HRNR expression levels were significantly higher in GC tissues than in the adjacent normal mucosa. HRNR expression level in GC tissue showed sex differences. The 5-year OS rate in the high-HRNR expression group was significantly worse than that in the low-expression group (5-year survival 53.6% vs. 74.9%; p=0.004). Furthermore, on multivariate analysis, high-HRNR expression was an independent predictor of poor OS (hazard ratio=1.534; 95% confidence interval=1.130-2.618; p=0.011).</p><p><strong>Conclusion: </strong>In patients with pStage II/III GC after curative gastrectomy, HRNR expression in GC tissue may be a useful prognostic marker.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"44 10","pages":"4579-4584"},"PeriodicalIF":1.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142339872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identifying High Recurrence Risk in Breast Carcinoma Patients Through Spatial Transcriptomic Analysis. 通过空间转录组分析识别乳腺癌患者的高复发风险
IF 1.6 4区 医学 Q4 ONCOLOGY Pub Date : 2024-10-01 DOI: 10.21873/anticanres.17268
Jinah Chu, Sung-Im DO, Hyun-Soo Kim

Background/aim: Comparing gene expression profiles according to recurrence risk using spatially resolved transcriptomic analysis has not been reported. This study aimed to identify distinct genetic features of breast carcinoma associated with a high Oncotype DX Recurrence Score (ORS).

Patients and methods: Patients were categorized into two groups, ORS-high (ORS-H; two patients) and ORS-non-high (ORS-NH; five patients). We performed digital spatial profiling and bioinformatic analyses to investigate the spatial transcriptomic profiles.

Results: Lysozyme (LYZ), complement C1q C chain (C1QC), and complement C1q B chain (C1QB) exhibited the highest fold changes in the stromal compartment of the ORS-H group. Gene ontology enrichment analysis of the ORS-H group revealed significant up-regulation of genes associated with immune response in the stromal compartment, including lymphocyte-mediated immunity, adaptive immune response related to the immunoglobulin superfamily, and leukocyte-mediated immunity. Gene set enrichment analysis showed significant positive enrichment of gene sets associated with interferon (IFN) response and complement pathways in the stromal compartment.

Conclusion: This study highlights significant differences in gene expression profiles and spatially resolved transcriptional activities between ORS-H and ORS-NH breast carcinomas. The significant up-regulation of genes and pathways associated with cell-mediated immunity, IFN response, and complement C1q in the stromal compartment of the ORS-H group warrants further evaluation with larger population cohorts.

背景/目的:利用空间分辨转录组分析比较复发风险的基因表达谱尚未见报道。本研究旨在确定与高Oncotype DX复发评分(ORS)相关的乳腺癌的不同遗传特征:将患者分为两组:ORS-高(ORS-H;两名患者)和ORS-非高(ORS-NH;五名患者)。我们进行了数字空间图谱分析和生物信息学分析,以研究空间转录组图谱:结果:溶菌酶(LYZ)、补体C1q C链(C1QC)和补体C1q B链(C1QB)在ORS-H组基质区的变化倍数最高。对 ORS-H 组进行的基因本体富集分析显示,基质区与免疫反应相关的基因显著上调,包括淋巴细胞介导的免疫、与免疫球蛋白超家族相关的适应性免疫反应和白细胞介导的免疫。基因组富集分析表明,基质区与干扰素(IFN)反应和补体途径相关的基因组明显正富集:本研究强调了ORS-H和ORS-NH乳腺癌在基因表达谱和空间分辨转录活性方面的显著差异。在ORS-H组的基质区,与细胞介导免疫、IFN反应和补体C1q相关的基因和通路明显上调,这值得在更大的人群队列中进行进一步评估。
{"title":"Identifying High Recurrence Risk in Breast Carcinoma Patients Through Spatial Transcriptomic Analysis.","authors":"Jinah Chu, Sung-Im DO, Hyun-Soo Kim","doi":"10.21873/anticanres.17268","DOIUrl":"https://doi.org/10.21873/anticanres.17268","url":null,"abstract":"<p><strong>Background/aim: </strong>Comparing gene expression profiles according to recurrence risk using spatially resolved transcriptomic analysis has not been reported. This study aimed to identify distinct genetic features of breast carcinoma associated with a high Oncotype DX Recurrence Score (ORS).</p><p><strong>Patients and methods: </strong>Patients were categorized into two groups, ORS-high (ORS-H; two patients) and ORS-non-high (ORS-NH; five patients). We performed digital spatial profiling and bioinformatic analyses to investigate the spatial transcriptomic profiles.</p><p><strong>Results: </strong>Lysozyme (LYZ), complement C1q C chain (C1QC), and complement C1q B chain (C1QB) exhibited the highest fold changes in the stromal compartment of the ORS-H group. Gene ontology enrichment analysis of the ORS-H group revealed significant up-regulation of genes associated with immune response in the stromal compartment, including lymphocyte-mediated immunity, adaptive immune response related to the immunoglobulin superfamily, and leukocyte-mediated immunity. Gene set enrichment analysis showed significant positive enrichment of gene sets associated with interferon (IFN) response and complement pathways in the stromal compartment.</p><p><strong>Conclusion: </strong>This study highlights significant differences in gene expression profiles and spatially resolved transcriptional activities between ORS-H and ORS-NH breast carcinomas. The significant up-regulation of genes and pathways associated with cell-mediated immunity, IFN response, and complement C1q in the stromal compartment of the ORS-H group warrants further evaluation with larger population cohorts.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"44 10","pages":"4387-4401"},"PeriodicalIF":1.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142339882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Palliative Radiation Treatment in Patients Managed With Advanced/Interventional Pain Therapy such as Pump-delivered Continuous Opioids. 采用先进的/介入性疼痛疗法(如泵给式连续阿片类药物)对患者进行姑息性放射治疗。
IF 1.6 4区 医学 Q4 ONCOLOGY Pub Date : 2024-10-01 DOI: 10.21873/anticanres.17271
Carsten Nieder, Stine M Jensen, Solveig Nilsen, Ellinor C Haukland

Background/aim: The study aim was to analyze the feasibility and efficacy of palliative radiotherapy in patients receiving advanced/interventional pain therapy, such as epidural or spinal anesthesia or subcutaneous pump delivery of opioids. Endpoints such as pain relief, treatment in the last month of life and survival were evaluated.

Patients and methods: Different baseline parameters including but not limited to age and Eastern Cooperative Oncology Group performance status (ECOG PS) were assessed. Outcomes were abstracted from electronic health records. The Edmonton Symptom Assessment System (ESAS) was utilized to score pain intensity.

Results: The study included 48 patients, 44 of whom completed radiotherapy as prescribed. Device malfunction was not observed. Overall, 31 patients (65%) had journal notes available allowing for evaluation of pain relief. Twenty-six of 31 experienced pain relief (54% in the intention-to-treat population of 48 study patients). Twelve patients (25%) stopped interventional pain therapy and were converted to transdermal or oral drugs. Median survival was 1.6 months. Forty-four percent had received radiotherapy during the last month of life. Sixty-four percent of patients with ECOG PS 3-4 had received radiotherapy during the last month of life, compared to 22% of those with ECOG PS <3, p=0.004.

Conclusion: Palliative radiotherapy was feasible in this setting, but given the short median survival and high likelihood of treatment during the last month of life, patient selection and choice of fractionation regimen should be optimized. The record review identified several patients who experienced worthwhile pain relief, sometimes leading to conversion of pain therapy back to non-invasive oral or transdermal application.

背景/目的:该研究旨在分析姑息放疗在接受晚期/介入性疼痛治疗(如硬膜外或脊髓麻醉或阿片类药物皮下泵给药)患者中的可行性和有效性。患者和方法:评估了不同的基线参数,包括但不限于年龄和东部合作肿瘤学组(Eastern Cooperative Oncology Group)表现状态(ECOG PS)。结果摘自电子健康记录。采用埃德蒙顿症状评估系统(ESAS)对疼痛强度进行评分:研究共纳入 48 名患者,其中 44 人按照医嘱完成了放疗。未发现设备故障。总体而言,31 名患者(65%)有日志记录,可以对疼痛缓解情况进行评估。31名患者中有26名疼痛缓解(在48名研究患者的意向治疗人群中占54%)。12名患者(25%)停止了介入止痛治疗,转为使用透皮或口服药物。中位生存期为 1.6 个月。44%的患者在生命的最后一个月接受了放疗。64%的ECOG PS 3-4患者在生命的最后一个月接受了放疗,而ECOG PS结论为3-4的患者只有22%接受了放疗:姑息放疗在这种情况下是可行的,但考虑到中位生存期较短以及在生命最后一个月接受治疗的可能性较高,应优化患者选择和分次治疗方案的选择。记录审查发现,有几名患者的疼痛得到了有效缓解,有时导致疼痛治疗转回非侵入性口服或透皮应用。
{"title":"Palliative Radiation Treatment in Patients Managed With Advanced/Interventional Pain Therapy such as Pump-delivered Continuous Opioids.","authors":"Carsten Nieder, Stine M Jensen, Solveig Nilsen, Ellinor C Haukland","doi":"10.21873/anticanres.17271","DOIUrl":"https://doi.org/10.21873/anticanres.17271","url":null,"abstract":"<p><strong>Background/aim: </strong>The study aim was to analyze the feasibility and efficacy of palliative radiotherapy in patients receiving advanced/interventional pain therapy, such as epidural or spinal anesthesia or subcutaneous pump delivery of opioids. Endpoints such as pain relief, treatment in the last month of life and survival were evaluated.</p><p><strong>Patients and methods: </strong>Different baseline parameters including but not limited to age and Eastern Cooperative Oncology Group performance status (ECOG PS) were assessed. Outcomes were abstracted from electronic health records. The Edmonton Symptom Assessment System (ESAS) was utilized to score pain intensity.</p><p><strong>Results: </strong>The study included 48 patients, 44 of whom completed radiotherapy as prescribed. Device malfunction was not observed. Overall, 31 patients (65%) had journal notes available allowing for evaluation of pain relief. Twenty-six of 31 experienced pain relief (54% in the intention-to-treat population of 48 study patients). Twelve patients (25%) stopped interventional pain therapy and were converted to transdermal or oral drugs. Median survival was 1.6 months. Forty-four percent had received radiotherapy during the last month of life. Sixty-four percent of patients with ECOG PS 3-4 had received radiotherapy during the last month of life, compared to 22% of those with ECOG PS <3, p=0.004.</p><p><strong>Conclusion: </strong>Palliative radiotherapy was feasible in this setting, but given the short median survival and high likelihood of treatment during the last month of life, patient selection and choice of fractionation regimen should be optimized. The record review identified several patients who experienced worthwhile pain relief, sometimes leading to conversion of pain therapy back to non-invasive oral or transdermal application.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"44 10","pages":"4419-4425"},"PeriodicalIF":1.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142339892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum. 更正。
IF 1.6 4区 医学 Q4 ONCOLOGY Pub Date : 2024-09-01 DOI: 10.21873/anticanres.17243
Syeda Hoorulain Ahmed
{"title":"Corrigendum.","authors":"Syeda Hoorulain Ahmed","doi":"10.21873/anticanres.17243","DOIUrl":"https://doi.org/10.21873/anticanres.17243","url":null,"abstract":"","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"44 9","pages":"4133"},"PeriodicalIF":1.6,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142091536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of Chemoradiotherapy on Locoregional Recurrence After Pancreatectomy for Pancreatic Cancer. 化放疗对胰腺癌胰腺切除术后局部复发的影响
IF 1.6 4区 医学 Q4 ONCOLOGY Pub Date : 2024-09-01 DOI: 10.21873/anticanres.17229
Michinori Matsumoto, Kenei Furukawa, Tadashi Uwagawa, Yoshihiro Shirai, Masashi Tsunematsu, Shinji Onda, Takeshi Gocho, Yuta Yamada, Koichiro Haruki, Toru Ikegami

Background/aim: The study aimed to investigate the efficacy of radiotherapy or chemoradiotherapy for isolated locoregional recurrence after pancreatectomy for pancreatic cancer.

Patients and methods: Twenty-eight patients who had isolated locoregional recurrence after pancreatectomy for pancreatic cancer between 2007 and 2021 were retrospectively analyzed. We investigated the effect of the treatment method [radiotherapy or chemoradiotherapy (radiotherapy with concurrent chemotherapy)] on progression-free survival (PFS) and post-recurrence survival (PRS).

Results: The median disease-free survival was 16.1 months (range=4.7-47.1 months). Five patients received radiotherapy and 21 patients received chemoradiotherapy [radiotherapy concurrent with gemcitabine (GEM) or S-1] for locoregional recurrence. All patients except one patient with interstitial pneumonia were treated with salvage chemotherapy after irradiation. The median PFS rates of the radiotherapy group and the chemoradiotherapy group were 2.8 months (range=1.5-5.4 months) and 16.8 months (range=2.7-42.8 months), respectively. The median PRS rates were 23.7 months (range=8.1-26.4 months) for the radiotherapy group and 26.2 months (range=6.0-64.7 months) for the chemoradiotherapy group. Multivariate analysis identified radiotherapy [hazard ratio (HR)=12.2, 95% confidence interval (CI)=3.29-45.6, p<0.001] and serum DUPAN-2 >150 U/ml (HR=2.90, 95%CI=1.22-6.93, p=0.02) as independent predictors of PFS, and UICC TNM Stage ≥III (HR=3.23, 95%CI=1.17-8.96, p=0.02) and modified Glasgow prognostic score before the treatment for the recurrence 1 or 2 (HR=3.05, 95%CI=1.15-8.08, p=0.03) as independent predictors of PRS.

Conclusion: Chemoradiotherapy for isolated locoregional recurrence after pancreatectomy for pancreatic cancer could suppress re-recurrence more effectively than radiotherapy.

背景/目的:该研究旨在探讨放疗或化放疗对胰腺癌胰腺切除术后孤立性局部复发的疗效:回顾性分析了2007年至2021年间胰腺癌胰腺切除术后出现孤立性局部复发的28例患者。我们研究了治疗方法[放疗或化放疗(放疗同时化疗)]对无进展生存期(PFS)和复发后生存期(PRS)的影响:中位无病生存期为16.1个月(范围=4.7-47.1个月)。5名患者接受了放疗,21名患者接受了化放疗[放疗同时使用吉西他滨(GEM)或S-1]治疗局部复发。除一名间质性肺炎患者外,所有患者均在放疗后接受了挽救性化疗。放疗组和化疗组的中位生存期分别为2.8个月(范围=1.5-5.4个月)和16.8个月(范围=2.7-42.8个月)。放疗组的中位PRS率为23.7个月(范围=8.1-26.4个月),化放疗组为26.2个月(范围=6.0-64.7个月)。多变量分析确定放疗[危险比(HR)=12.2,95%置信区间(CI)=3.29-45.6,p150 U/ml(HR=2.90,95%CI=1.22-6.93,P=0.02)为PFS的独立预测因素,UICC TNM分期≥III(HR=3.23,95%CI=1.17-8.96,p=0.02)和复发1或2期治疗前的改良格拉斯哥预后评分(HR=3.05,95%CI=1.15-8.08,p=0.03)作为PRS的独立预测指标:结论:胰腺癌胰腺切除术后局部复发的化疗放疗比放疗能更有效地抑制复发。
{"title":"Effect of Chemoradiotherapy on Locoregional Recurrence After Pancreatectomy for Pancreatic Cancer.","authors":"Michinori Matsumoto, Kenei Furukawa, Tadashi Uwagawa, Yoshihiro Shirai, Masashi Tsunematsu, Shinji Onda, Takeshi Gocho, Yuta Yamada, Koichiro Haruki, Toru Ikegami","doi":"10.21873/anticanres.17229","DOIUrl":"https://doi.org/10.21873/anticanres.17229","url":null,"abstract":"<p><strong>Background/aim: </strong>The study aimed to investigate the efficacy of radiotherapy or chemoradiotherapy for isolated locoregional recurrence after pancreatectomy for pancreatic cancer.</p><p><strong>Patients and methods: </strong>Twenty-eight patients who had isolated locoregional recurrence after pancreatectomy for pancreatic cancer between 2007 and 2021 were retrospectively analyzed. We investigated the effect of the treatment method [radiotherapy or chemoradiotherapy (radiotherapy with concurrent chemotherapy)] on progression-free survival (PFS) and post-recurrence survival (PRS).</p><p><strong>Results: </strong>The median disease-free survival was 16.1 months (range=4.7-47.1 months). Five patients received radiotherapy and 21 patients received chemoradiotherapy [radiotherapy concurrent with gemcitabine (GEM) or S-1] for locoregional recurrence. All patients except one patient with interstitial pneumonia were treated with salvage chemotherapy after irradiation. The median PFS rates of the radiotherapy group and the chemoradiotherapy group were 2.8 months (range=1.5-5.4 months) and 16.8 months (range=2.7-42.8 months), respectively. The median PRS rates were 23.7 months (range=8.1-26.4 months) for the radiotherapy group and 26.2 months (range=6.0-64.7 months) for the chemoradiotherapy group. Multivariate analysis identified radiotherapy [hazard ratio (HR)=12.2, 95% confidence interval (CI)=3.29-45.6, p<0.001] and serum DUPAN-2 >150 U/ml (HR=2.90, 95%CI=1.22-6.93, p=0.02) as independent predictors of PFS, and UICC TNM Stage ≥III (HR=3.23, 95%CI=1.17-8.96, p=0.02) and modified Glasgow prognostic score before the treatment for the recurrence 1 or 2 (HR=3.05, 95%CI=1.15-8.08, p=0.03) as independent predictors of PRS.</p><p><strong>Conclusion: </strong>Chemoradiotherapy for isolated locoregional recurrence after pancreatectomy for pancreatic cancer could suppress re-recurrence more effectively than radiotherapy.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"44 9","pages":"4003-4010"},"PeriodicalIF":1.6,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142091537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Helicobacter pylori Infection Affects the Tumor Immune Microenvironment of Esophageal Cancer Patients. 幽门螺杆菌感染影响食管癌患者的肿瘤免疫微环境
IF 1.6 4区 医学 Q4 ONCOLOGY Pub Date : 2024-09-01 DOI: 10.21873/anticanres.17205
Hiroki Matsuda, Kota Iwahori, Tomohira Takeoka, Ryo Kato, Shinya Urakawa, Takuro Saito, Tomoki Makino, Hidetoshi Eguchi, Yuichiro Doki, Hisashi Wada

Background/aim: We herein examined T cell immunity in esophageal cancer patients with and without Helicobacter pylori infection to establish a foundation for immunotherapeutic strategies targeting esophageal cancer in the presence of H. pylori infection.

Materials and methods: Twenty-six patients with esophageal squamous cell carcinoma between 2015 and 2017 were enrolled in the present study. Serum antibodies against H. pylori were measured. Fresh tumor tissues were obtained by endoscopic biopsy or from surgical resection. A cell suspension of these tissues was subjected to a flow cytometric analysis.

Results: Among the 26 patients analyzed, 10 (38.5%) were seropositive for H. pylori. The flow cytometric analysis of tumor-infiltrating lymphocytes revealed that the percentage of CD103+CD4+ T cells in esophageal tumors was significantly lower in H. pylori-positive patients than in H. pylori-negative patients (p=0.0105). Conversely, the percentage of CD45RA-CD25hi effector Treg cells in esophageal tumors was significantly higher in H. pylori-positive patients than in H. pylori-negative patients (p=0.0022), indicating an immunosuppressive tumor microenvironment in the former. Following neoadjuvant chemotherapy, the number of CD45RA-CD25hi effector Treg cells decreased (p=0.0248).

Conclusion: The tumor immune microenvironment of esophageal cancer patients with H. pylori infection exhibited an immunosuppressive phenotype. The targeting of Treg cells has potential in immunotherapy for this patient population.

背景/目的:我们在此研究了幽门螺杆菌感染和未感染幽门螺杆菌的食管癌患者的T细胞免疫,为幽门螺杆菌感染情况下针对食管癌的免疫治疗策略奠定基础:本研究共纳入了26例2015年至2017年间的食管鳞状细胞癌患者。测定了血清中的幽门螺杆菌抗体。通过内镜活检或手术切除获得新鲜肿瘤组织。对这些组织的细胞悬液进行流式细胞分析:在分析的 26 名患者中,10 人(38.5%)幽门螺杆菌血清反应呈阳性。肿瘤浸润淋巴细胞的流式细胞分析显示,幽门螺杆菌阳性患者食管肿瘤中 CD103+CD4+ T 细胞的比例明显低于幽门螺杆菌阴性患者(P=0.0105)。相反,幽门螺杆菌阳性患者食管肿瘤中CD45RA-CD25hi效应Treg细胞的比例明显高于幽门螺杆菌阴性患者(p=0.0022),表明前者存在免疫抑制性肿瘤微环境。新辅助化疗后,CD45RA-CD25hi效应Treg细胞数量减少(p=0.0248):结论:幽门螺杆菌感染的食管癌患者的肿瘤免疫微环境表现出免疫抑制表型。以Treg细胞为靶点的免疫疗法在这类患者中具有潜力。
{"title":"<i>Helicobacter pylori</i> Infection Affects the Tumor Immune Microenvironment of Esophageal Cancer Patients.","authors":"Hiroki Matsuda, Kota Iwahori, Tomohira Takeoka, Ryo Kato, Shinya Urakawa, Takuro Saito, Tomoki Makino, Hidetoshi Eguchi, Yuichiro Doki, Hisashi Wada","doi":"10.21873/anticanres.17205","DOIUrl":"https://doi.org/10.21873/anticanres.17205","url":null,"abstract":"<p><strong>Background/aim: </strong>We herein examined T cell immunity in esophageal cancer patients with and without Helicobacter pylori infection to establish a foundation for immunotherapeutic strategies targeting esophageal cancer in the presence of H. pylori infection.</p><p><strong>Materials and methods: </strong>Twenty-six patients with esophageal squamous cell carcinoma between 2015 and 2017 were enrolled in the present study. Serum antibodies against H. pylori were measured. Fresh tumor tissues were obtained by endoscopic biopsy or from surgical resection. A cell suspension of these tissues was subjected to a flow cytometric analysis.</p><p><strong>Results: </strong>Among the 26 patients analyzed, 10 (38.5%) were seropositive for H. pylori. The flow cytometric analysis of tumor-infiltrating lymphocytes revealed that the percentage of CD103<sup>+</sup>CD4<sup>+</sup> T cells in esophageal tumors was significantly lower in H. pylori-positive patients than in H. pylori-negative patients (p=0.0105). Conversely, the percentage of CD45RA-CD25hi effector Treg cells in esophageal tumors was significantly higher in H. pylori-positive patients than in H. pylori-negative patients (p=0.0022), indicating an immunosuppressive tumor microenvironment in the former. Following neoadjuvant chemotherapy, the number of CD45RA-CD25hi effector Treg cells decreased (p=0.0248).</p><p><strong>Conclusion: </strong>The tumor immune microenvironment of esophageal cancer patients with H. pylori infection exhibited an immunosuppressive phenotype. The targeting of Treg cells has potential in immunotherapy for this patient population.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"44 9","pages":"3799-3805"},"PeriodicalIF":1.6,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142091631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Expression Analysis of SSTR 1, 2 and 3 in Small-cell Lung Cancer Patients as Targets for Future Peptide Receptor Radionuclide Therapy. 作为未来肽受体放射性核素疗法靶点的小细胞肺癌患者 SSTR 1、2 和 3 的表达分析。
IF 1.6 4区 医学 Q4 ONCOLOGY Pub Date : 2024-09-01 DOI: 10.21873/anticanres.17206
Nitzan Sagie, Elizabeth Romanov, Yarden Kezerle, Amichay Meirovitz, Kim Sheva

Background/aim: Small-cell lung cancer (SCLC) is noted for its high proliferative rate, and while treatable, relapse is common. SCLC is known to potentially express somatostatin receptors (SSTRs). Somatostatin possesses antineoplastic activity through cell-cycle arrest and apoptosis, and angiogenesis inhibition. SSTRs, thus, serve as potential anticancer targets for somatostatin analogue therapies. The aim of the study was to determine the expression rate of SSTR subtypes 1, 2 and 3 in SCLC using immunohistochemistry, and potential predictors of such rates.

Materials and methods: A total of 147 human, SCLC paraffin-embedded tissue microarrays with corresponding patient age, sex, TNM staging, and disease stage were utilized. Immunohistochemical analysis was performed using anti-SSTR 1, 2 and 3 antibodies, each calibrated using healthy human pancreatic islets as positive controls. Array slides were counterstained with hematoxylin and scored based on stain intensity and percentage of stained cells.

Results: No SCLC samples expressed SSTR 1, whereas SSTR 2 and 3 were expressed in 29.4% and 4.35% of cases respectively. While females had higher expression levels of SSTR 2/3, and there was a trend of decreased SSTR 2 expression with increased age, results were not statistically significant. No correlation between disease stage and SSTR expression was found. Co-expression of both SSTR2 and 3 occurred in 5.3% of patients.

Conclusion: Immunohisto-chemistry is an efficient screening tool to reveal optimum SCLC patients for somatostatin analogue therapy. Whilst there currently exist no accepted norm or predictors of SSTR expression levels in SCLC patients, this study contributes insight into the receptors' varied expression.

背景/目的:小细胞肺癌(SCLC)以增殖率高而著称,虽然可以治疗,但复发很常见。已知小细胞肺癌可能表达体生长抑素受体(SSTR)。体生长抑素通过抑制细胞周期、细胞凋亡和血管生成而具有抗肿瘤活性。因此,体生长激素受体是体生长激素类似物疗法的潜在抗癌靶点。本研究的目的是利用免疫组化方法确定SSTR亚型1、2和3在SCLC中的表达率,以及这些表达率的潜在预测因素:共使用了 147 个人类 SCLC 石蜡包埋组织芯片,并附有相应的患者年龄、性别、TNM 分期和疾病分期。使用抗 SSTR 1、2 和 3 抗体进行免疫组化分析,每种抗体均以健康人胰岛作为阳性对照进行校准。用苏木精对阵列切片进行反染,并根据染色强度和染色细胞的百分比进行评分:结果:没有 SCLC 样本表达 SSTR 1,而表达 SSTR 2 和 3 的病例分别占 29.4% 和 4.35%。女性的 SSTR 2/3 表达水平较高,而且随着年龄的增长,SSTR 2 的表达呈下降趋势,但结果无统计学意义。未发现疾病分期与 SSTR 表达之间存在相关性。5.3%的患者同时表达 SSTR2 和 SSTR3:免疫组化是一种有效的筛查工具,能发现最适合接受体生长激素类似物治疗的 SCLC 患者。虽然目前还没有公认的SCLC患者体内SSTR表达水平的标准或预测指标,但这项研究有助于深入了解受体的不同表达。
{"title":"Expression Analysis of SSTR 1, 2 and 3 in Small-cell Lung Cancer Patients as Targets for Future Peptide Receptor Radionuclide Therapy.","authors":"Nitzan Sagie, Elizabeth Romanov, Yarden Kezerle, Amichay Meirovitz, Kim Sheva","doi":"10.21873/anticanres.17206","DOIUrl":"10.21873/anticanres.17206","url":null,"abstract":"<p><strong>Background/aim: </strong>Small-cell lung cancer (SCLC) is noted for its high proliferative rate, and while treatable, relapse is common. SCLC is known to potentially express somatostatin receptors (SSTRs). Somatostatin possesses antineoplastic activity through cell-cycle arrest and apoptosis, and angiogenesis inhibition. SSTRs, thus, serve as potential anticancer targets for somatostatin analogue therapies. The aim of the study was to determine the expression rate of SSTR subtypes 1, 2 and 3 in SCLC using immunohistochemistry, and potential predictors of such rates.</p><p><strong>Materials and methods: </strong>A total of 147 human, SCLC paraffin-embedded tissue microarrays with corresponding patient age, sex, TNM staging, and disease stage were utilized. Immunohistochemical analysis was performed using anti-SSTR 1, 2 and 3 antibodies, each calibrated using healthy human pancreatic islets as positive controls. Array slides were counterstained with hematoxylin and scored based on stain intensity and percentage of stained cells.</p><p><strong>Results: </strong>No SCLC samples expressed SSTR 1, whereas SSTR 2 and 3 were expressed in 29.4% and 4.35% of cases respectively. While females had higher expression levels of SSTR 2/3, and there was a trend of decreased SSTR 2 expression with increased age, results were not statistically significant. No correlation between disease stage and SSTR expression was found. Co-expression of both SSTR2 and 3 occurred in 5.3% of patients.</p><p><strong>Conclusion: </strong>Immunohisto-chemistry is an efficient screening tool to reveal optimum SCLC patients for somatostatin analogue therapy. Whilst there currently exist no accepted norm or predictors of SSTR expression levels in SCLC patients, this study contributes insight into the receptors' varied expression.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"44 9","pages":"3807-3812"},"PeriodicalIF":1.6,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142091633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Anticancer research
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1